Story perspectives

AstraZeneca to Offer 80% Discounts, Create 3,600 Jobs

10/12/2025

Summary

Story summary

AstraZeneca PLC, the drugmaker, and the Trump administration finalized a deal to apply most-favored-nation pricing to Medicaid drugs.
The announcement was made on October 10, 2025, following a similar pact with Pfizer.
AstraZeneca will offer discounts up to 80% on select medications via the TrumpRx.gov platform launching in 2026.
In return, the company gains a three-year tariff exemption and commits $50 billion for U.S. manufacturing, creating about 3,600 Virginia jobs.

History

Historical Context

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 established Medicare Part D, allowing private plans to manage drug pricing without federal negotiation, leading to significant price increases. In 2022, the Inflation Reduction Act began permitting Medicare to negotiate prices, reflecting ongoing efforts to address the U.S.'s $600 billion annual prescription drug spending and improve affordability for patients.

1 of 2

Story summary

AstraZeneca PLC, the drugmaker, and the Trump administration finalized a deal to apply most-favored-nation pricing to Medicaid drugs.
The announcement was made on October 10, 2025, following a similar pact with Pfizer.
AstraZeneca will offer discounts up to 80% on select medications via the TrumpRx.gov platform launching in 2026.
In return, the company gains a three-year tariff exemption and commits $50 billion for U.S. manufacturing, creating about 3,600 Virginia jobs.

1 / 2